A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Sponsor
Karsten Gavenis
Study ID
NCT04524208
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Cabozantinib is administered orally at the dose of 60 mg per day..

Study Details

The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.

Key Dates

Start date
Mar 1, 2021
Status verified
Aug 2024
Primary completion
Sep 30, 2024
Completion
Oct 31, 2024

Study Design

Enrollment
45 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment-Arm

Primary Outcome Measure

Evaluate the efficacy of Cabozantinib treatment via DCR after 6 months. [ Time Frame: 6 months ]

Related Studies